The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
|Brand Name||Generic Name||Therapeutic Area||Recommendation Type||Project Status Sort descending||Date Submission Received||Date Recommendation Issued|
|Colorectal Cancer||In Progress|
|Unituxin||dinutuximab||Neuroblastoma||Reimburse with clinical criteria and/or conditions||Completed|
|Pradaxa||Dabigatran etexilate||Atrial fibrillation prevention of stroke and systemic embolism||Cancelled|
|Twynsta||Telmisartan / Amlodipine||Hypertension||Cancelled|
|BuTrans||Buprenorphine transdermal patch||Pain, persistent (moderate intensity)||Cancelled|
|Targin||Oxycodone / naloxone||Pain, Moderate to severe and relief of opioid-induced constipation||Cancelled|